Yüklüyor......
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Chinês |
| Baskı/Yayın Bilgisi: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
| Seri Bilgileri: | Chinese Journal of Lung Cancer |
| Konular: | |
| Online Erişim: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|